Dr. Richard Furman on Surprising Early Trial Results for Ibrutinib

We were all surprised, pleasantly surprised.

Dr. Furman did the first phase 1 study on ibrutinib. I remember him mentioning this trial to me years ago and it seemed to me such a long shot.

Not any more.

Thanks to those who had the courage to try something new. They were the real pioneers. We who are in the phase 2 and 3 trials are all in their debt.

And those who are eventually prescribed this drug or GS-1101 or others should look kindly on those of us who earlier make the decision, took a much lesser but still significant risk and entered a phase 2 or 3 trials.